Amifostine: Present and future in cytoprotection;Amifostine: Applications actuelles et perspectives en cytoprotection

Bulletin du Cancer

Volumn 83, Issue 9, 1996, Pages 773-787

  Lenoble, M ^a  

^a Centre Hospitalier Intercommunal Le Raincy Montfermeil   (France)

Author keywords

alkylating agents; amifostine; chemoprotection; experimental studies; ovarian carcinoma; phase III trial; radioprotection; side effects of cytotoxic chemotherapy

Indexed keywords

AMIFOSTINE; CISPLATIN; CYCLOPHOSPHAMIDE;

BLOOD TOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; OVARY CARCINOMA; PHASE 3 CLINICAL TRIAL; RADIATION PROTECTION;

AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; DISEASE MODELS, ANIMAL; DRUG TOLERANCE; HEMATOPOIETIC STEM CELLS; HUMANS; KIDNEY; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY;

EID: 0029759245     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Avril M, Ortoli J, Fortier-Beaulieu M et al. High-close cisplatin and WR-2721 in metastatic melanoma. Proc Am Soc Clin Oncol 1992;11:344
2. Bhanumathi P, Salesh EB, Vasudevan DM. Creatine phosphokinase and cardiotoxicity in adriamycin chemotherapy and its modification by WR-1065. Biochem Arch 1992;8:335-8
3. Budd GT, Bukowski RM, Murthy S et al. Randomized trial of carboplatin (CBDCA) vs CBDCA + amifostine in advanced malignancy. Proc Am Soc Clin Oncol 1994;13:442
4. Constine LS, Zagars G, Rubin P et al. Protection by WR-2721 of human bone marrow function following irradiation. Int J Radiat Oncol Biol Phys 1986;12:1505-8
5. Dorr RT, Bozak KA, Shipp NG, Hendrix M, Alberts DS, Ahmann F. In vitro rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratios. Cancer Res 1988;48:5222-7
6. Dorr RT, Lagel KE. Anthracycline cardioprotection by amifostine (WR-2721) and its active metabolite (WR-1065) in vitro [Abstract 1495]. Proc Am Soc Clin Oncol 1994;13:435
7. Douay L, Gorin NC, Gerota I, Najman A, Duhamel G. In vitro treatment of leukemic bone marrow for autologous transplantation. Exp Hematol 1982;10(suppl 12):113
8. Douay L, Hu C, Giarratana MC, Gorin NC. Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants. Semin Oncol 1994;21(suppl 11):16-20
9. Douay L, Laporte JP, Mary JY. Differences in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA-Z 7557). Bone Marrow Transplant 1987;2:33-43
10. Gandara DR, Nahhas WA, Adelson MD et al. Randomized placebo controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin induced toxicities. J Clin Oncol 1995;13:490-6
11. Glover D, Glick J, Weiler C, Fox K, Guerry D. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987,5:574-8
12. Gorin NC, Douay L, Laporte JP et al. Autologous bone marrow transplantation using marrow incubated with ASTA Z 7557 in adult acute leukemia. Blood 1986;67:1367-76
13. Green D, Wright A, Schein P, Clarke R, Lombardi VT. WR-2721 chemoprotection of doxorubicin toxicity in mice. Proc Am Assoc Cancer Res 1992;33:490
14. Kligerman MM, Liu TF, Liu Y et al. Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721. Int J Radiat Oncol Biol Phys 1992;22:799-802
15. Kligerman MM, Turrist AT, Urtasun RC et al. Final report of phase I trial of WR-2721 before protracted fractionated radiation therapy. Int J Radiat Oncol Biol Phys 1988;14:1119-22
16. Korst AEC, Gall HE, Vermorken JB, Fichtinger-Schepman AMJ, Van der Vijgh WJF. Influence of amifostine (AMI) on the pharmacokinetics (PK) of carboplatin (CARBO) in patients with solid tumors. Proc Am Soc Clin Oncol 1995;14:172
17. Korst AEC, Van der Vijgh WJF, Van de Sterre MLT, Fichtinger-Schepman AMJ, Vermorken JB, Boven E. Influence of amifostine on the ami tumor activity, pharmacokinetics and pharmacodynamics of carboplatin in nude mice [Abstract 071]. Proceedings of the 7th International Symposium on platinum and other metal coordination compounds in cancer chemotherapy, 1995
18. List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL. Amifostine is a novel stimulant of bone marrow progenitor growth in myelodysplastic syndromes [Abstract 1327]. Blood 1995;86(suppl 1):335a
19. Ma J, Verweij J, Planting AST, de Boer-Dennert M, Van der Burg MEL, Stoter G, Schellens JHM. Pharmacokinetic-dynamic relationship of weekly high dose cisplatin (C) in solid tumor patients (PTS) [Abstract]. Proc Am Soc Clin Oncol 1994;13:133
20. McColloch W, Scheffer BJ, Schein PS. New protective agents for bone marrow in cancer therapy. Cancer Invest 1991;9:279-87
21. McDonald S, Meyerowitz C, Smudzin T, Rubin P. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 1994;29:747-54
22. McVittie TJ, Brandenburg R, Farese AM, Patchen ML, Weiss J. Enhanced recovery from supralethal radiation exposure using combined modality WR-2721 plus recombinant human (rh) G-CSF. Proc Am Assoc Cancer Res 1992;33:505
23. Merrouche Y, Catimel G, Clavel M. Hematopoietic growth factors and chemoprotectants: should we move toward a two-step process for phase I clinical trials? Ann Oncol 1993;4:471-4
24. Milas L, Hunter NR, Stephens LC, Peters LJ. Inhibilion of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1984;44:5567-9
25. Millar J, McElwain T, Clutterbuck R, Wist E. The modification of melphalan toxicity in tumor-bearing mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR 2721). Am J Clin Oncol 1982;5:321-8
26. Mollman JE, Glover DJ, Hogan WM, Furman RE. Cisplatin neuropathy. Risk factors, prognosis and protection by WR-2721. Cancer 1988;61:2129-5
27. Nagy B, Dale PJ, Grdina DJ. Protection against cis-diamminedichloroplatinum cytotoxicity and mutagenicity in V79 cells by 2-[(aminopropyl)amino]ethanethiol. Cancer Res 1986;46:1132-5
28. Ohnishi ST, Ohnishi T, Glick JH, Schein PS. In vitro study on the antioxidant activities of amifostine (WR-2721). Proc Am Assoc Cancer Res 1992;33:419
29. Peters GJ, Van der Vijgh WJF. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects. Eur J Cancer 1995;31A (suppl 1):S1-S7
30. Planting AST, Vermorken JB, Catinel G et al. Randomized phase II study of weekly cisplatin with or without amifostine in patients with advanced head and neck cancer. Eur J Cancer 1995; 31A(suppl 5):S85
31. Romanul FCA, Bannister RG. Localized areas of high alkaline phosphatase acticity in endothelium of arteries. Nature 1962;195:611-2
32. Schiller JH, Storer B, Berlin J et al. Amifostine, cisplatin and vinblastine in metastatic non-small cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 1996;14:1913-21
33. Schuchter LM, Luginbuhl WE, Meropol NJ. The current status of toxicity protectants in cancer therapy. Semin Oncol 1992; 19:742-51
34. ®, amifostine) in the Balb/c mouse. Drug Metab Dispos 1994;22:895-902
35. Shaw LM, Bonner HS, Turrisi A, Norfleet AL, Kligerman M. Measurement of S-2-(3-aminopropyl-amino) ethanethiol (WR-1065) in blood and tissue. J Liq Chromatogr 1986;9:8445-59
36. Shaw LM, Glover D, Turrisi A et al. Pharmacokinetics of WR-2721. Pharm Ther 1988;39:195-201
37. Shpall EJ, Stemmer SM, Hami L et al. Amifostine (WR-2721) shortens the engraftment time of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 1994;83:3132-7
38. Tigaud JD, Demolombe S, Bastion Y, Bryon PA, Coiffier B. Ifosfamide continuous infusion plus etoposide in the treatment of elderly patients with aggressive lymphoma: a phase II study. Hematol Oncol 1991;9:225-33
39. Treskes M, Boven E, Van de Loosdrecht AA et al. Effects of the modulating agent WR-2721 on myelotoxicity and antitumor activity in carboplatin-treated mice. Eur J Cancer 1994;30A:183-7
40. Treskes M, Nijtmans LGJ, Fichtinger-Schepman AMJ, Van der Vijgh WJF. Effects of the modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison ot the effects of thiosulfate and diethyldithiocarbamate. Biochem Pharmacol 1992;43:1013-9
41. Utley JF, Marlowe C, Waddell WJ. Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse. Radiat Res 1976;68:284-91
42. Valeriote F, Token S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 1982;42:4330-1
43. Van der Vijgh, Peters GJ. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects. Semin Oncol 1994;21(suppl 11):2-7
44. Vermorken JB, Punt CJA, Eeltink CM et al. Phase I trial of carboplatin and amifostine (WR-2721) [Abstract 1432]. Proc Am Assoc Cancer Res 1995;36:240
45. ®). Semin Oncol 1994;21(suppl 11):211-25
46. Wassermann TH, Philips TL, Ross G, Kane LJ. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials 1981;4:3-6
47. Yuhas JM. Radioprotective and toxic effects of S-2-(3 aminopropylamino) ethylphosphorothioic acid (WR-2721) on the development of immunocompetent cells. Cell Immunol 1972;4:256-63
48. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1980;40:1519-24